Document Detail

Use of cytomegalovirus hyperimmunoglobulin for prevention of congenital cytomegalovirus disease: a retrospective analysis.
MedLine Citation:
PMID:  22752777     Owner:  NLM     Status:  In-Data-Review    
Abstract Aims: The aim of this study was to investigate the current prenatal "off-label use" of cytomegalovirus hyperimmunoglobulin (CMV-HIG) in the prevention and treatment of congenital CMV (cCMV) infection, including the long-term outcome of the children. Methods: This retrospective observational study comprised mothers and their children, born between January 1, 2006, and October 30, 2010. Prenatal CMV-HIG was administered after diagnosis of primary CMV infection of the mother. Clinical and virological data were collected from maternal and pediatric medical and laboratory reports. Follow-up was 12-36 months after birth. Results: Forty-two women and 43 children met the study criteria. In total, 40 mothers and six unborn infants received 115 doses of CMV-HIG. The treatment group (TG; CMV-DNA polymerase chain reaction-positive amniotic fluid) included four mothers; the multinomial group (MG; CMV-positive mother and unknown CMV status of fetus) included 38 mothers (39 infants). For the four unborn infants in TG, CMV-HIG was administered either intraumbilically or into the amniotic fluid; three of the four mothers received intravenous CMV-HIG. Three children in TG remained CMV-positive and were asymptomatic at birth and during follow-up. One infant in TG had symptomatic cCMV infection in utero, at birth, and during follow-up. In MG, 37 of 38 women received intravenous CMV-HIG and two of 39 infants received CMV-HIG in utero. In total, 9 (23.1%) of 39 children in MG were positive for cCMV (including a terminated pregnancy). All eight instances of cCMV infection at birth in MG were asymptomatic at birth and during follow-up. The fetus from the terminated pregnancy showed no sonographic symptoms of cCMV infection. No severe side effect occurred in 115 CMV-HIG applications. Conclusion: CMV-HIG was well tolerated. Compared with published untreated mother-child pairs, we observed a trend toward a smaller risk for intrauterine CMV transmission following CMV-HIG application. Signs of prenatal cCMV disease were not reversed after CMV-HIG.
Horst Buxmann; Otto M V Stackelberg; Rolf L Schlößer; Gisela Enders; Markus Gonser; Matthias Meyer-Wittkopf; Klaus Hamprecht; Martin Enders
Related Documents :
22824627 - Performance of the integrated management of childhood illness algorithm for diagnosis o...
25169157 - Interaction between maternal prepregnancy body mass index and gestational weight gain s...
20659937 - Randomised controlled trial of prophylactic fluconazole versus nystatin for the prevent...
724317 - Control of nosocomial respiratory syncytial viral infections.
20367617 - The development of the subplate and thalamocortical connections in the human foetal brain.
11562617 - Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors...
Publication Detail:
Type:  Journal Article     Date:  2012-03-27
Journal Detail:
Title:  Journal of perinatal medicine     Volume:  40     ISSN:  1619-3997     ISO Abbreviation:  J Perinat Med     Publication Date:  2012  
Date Detail:
Created Date:  2012-07-03     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0361031     Medline TA:  J Perinat Med     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  439-46     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  An open-label, randomized efficacy and safety trial of subcutaneous and intramuscular BT088 (Fovepta...
Next Document:  Therapeutic hypothermia and hypoxic ischemic encephalopathy: opinion and practice of pediatricians i...